Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent IDH1/2 Mutated Glioma”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Early research (Phase 1)Active Not RecruitingNCT03749187
What this trial is testing

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Who this might be right for
GlioblastomaIDH1 Gene MutationIDH2 Gene Mutation+7 more
University of California, San Francisco 78
Not applicableUnknownNCT02333513
What this trial is testing

Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Who this might be right for
Recurrent High-grade Glioma
Hebei Yanda Hospital 100
Very early researchActive Not RecruitingNCT05406700
What this trial is testing

Niraparib In Recurrent IDH 1/2 Gliomas

Who this might be right for
Low-grade GliomaIDH2 Gene MutationRecurrent Glioma+2 more
Massachusetts General Hospital 16
Testing effectiveness (Phase 2)Study completedNCT03914742
What this trial is testing

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Who this might be right for
IDH1 MutationIDH2 MutationRecurrent Glioblastoma+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 67
Testing effectiveness (Phase 2)Looking for participantsNCT05588141
What this trial is testing

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Who this might be right for
Brain TumorCancer
National Cancer Institute (NCI) 96
Large-scale testing (Phase 3)Active Not RecruitingNCT06780930
What this trial is testing

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Who this might be right for
Residual or Recurrent Grade 2 IDH Mutant Glioma
Servier 57
Large-scale testing (Phase 3)Active Not RecruitingNCT04164901
What this trial is testing

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Who this might be right for
Grade 2 GliomaResidual GliomaRecurrent Glioma
Institut de Recherches Internationales Servier 331
Testing effectiveness (Phase 2)UnknownNCT03666559
What this trial is testing

Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation

Who this might be right for
Recurrent IDH1/2 Mutated Glioma
Assistance Publique - Hôpitaux de Paris 8